TNFRSF9 and neoplasm: Other methods rely on the selection of TILs expressing certain surface markers such as PD-1, CD39 or CD103, or CD137 (45–51), which can reduce overall cell yield and bias selection toward exhausted or terminally differentiated clones (52–55), potentially excluding less-differentiated, tumor-reactive clonotypes.